In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Stelljes M, Middeke JM, Bug G, Wagner EM, Mueller LP, Christoph S, Krause S, Bethge W, Jost E, Platzbecker U, Klein S, Schubert J, Niederland J, Kaufmann M, Schaefer-Eckart K, Schaich M, Baldauf H, Stoelzel F, Petzold C, Roellig C, Alakel N, Steffen B, Hauptrock B, Reicherts C, Schliemann C, Serve H, Schmidt AH, Bornhaeuser M, Mikesch JH, Schetelig J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA

DOI: 10.1182/blood-2022-159962

Authors with CRIS profile

Involved external institutions

Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Technische Universität Dresden Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) DKMS Deutsche Knochenmarkspenderdatei Germany (DE) Westfälische Wilhelms-Universität (WWU) Münster Germany (DE) Universitätsklinikum Tübingen Germany (DE) Rems-Murr-Kliniken Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) HELIOS Kliniken Germany (DE) Universitätsklinikum Augsburg Germany (DE) Elblandkliniken Germany (DE) Universitätsklinikum Mannheim Germany (DE) Paracelsus Medizinische Privatuniversität Austria (AT) Martin-Luther-Universität Halle-Wittenberg (MLU) Germany (DE) Universitätsklinikum Leipzig Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Robert-Bosch-Krankenhaus Germany (DE)

How to cite

APA:

Stelljes, M., Middeke, J.M., Bug, G., Wagner, E.-M., Mueller, L.P., Christoph, S.,... Schetelig, J. (2022). In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial. In BLOOD. New Orleans, LA: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Stelljes, Matthias, et al. "In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022.

BibTeX: Download